UNSPSC 51123109: Epicainide

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DZY7AR1B0U. European Medicines Agency schedules Epicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06562MIG. Epicainide generally arises in the molecular formula C21H26N2O2.

UNSPSC 51123109 Epicainide, a Commodity code, represents medications and pharmaceutical products that state and local government health agencies, fire rescue departments, and benefits programs procure for emergency medical response, institutional care, and employee health plan administration. The code captures advanced life support medications and prescription pharmaceuticals that governments source through both direct vendor contracting and cooperative purchasing arrangements. State and local issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating pharmaceutical supply across multiple jurisdictions and member agencies.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026) specifying 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with estimated contract value of $40,000.00 and a one-year term plus two optional one-year renewals. The Texas Health and Human Services Commission issued RFI No. HHS0017013 (posted April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription fulfillment programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802, due March 26, 2026) requiring vendors to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026 and a two-year initial term. The MMCAP solicitation emphasizes price competitiveness (75 percent evaluation weight), cGMP and DSCSA compliance, and wholesaler integration, while the Tampa bid includes a 5 percent Small Local Business Enterprise discount not to exceed $10,000.